SYDNEY, Sept. 8,
2022 /PRNewswire/ -- Kazia Therapeutics Limited
(NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development
company, today announced that final data from its phase II study of
paxalisib in patients with newly diagnosed glioblastoma will be the
subject of an oral presentation at the upcoming annual congress of
the European Society for Medical Oncology (ESMO), which will be
held in person from 9-13 September
2022 in Paris, France.
The oral presentation will summarise key findings of the
completed phase II study of paxalisib in glioblastoma, which was
previously the subject of a poster presentation at the American
Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, in June
2022. The presentation will provide additional detail on
pharmacokinetics and pharmacodynamics. The presentation will be
delivered by Professor John de
Groot, Division Chief of Neuro-Oncology at the University of California, San Francisco, one of the
principal investigators on the study.
ORAL
PRESENTATION
|
|
Title:
|
Pharmacokinetics and
pharmacodynamics of paxalisib in newly diagnosed glioblastoma
patients with unmethylated MGMT promoter status: Final phase II
study results.
|
Date:
|
Friday, 9
September
|
Session:
|
CNS Tumours
|
Abstract
ID:
|
2800
|
For More
Information, Please Contact:
|
|
|
In the United
States:
Joe Green
Edison Investor
Relations
jgreen@edisongroup.com
Phone: +1
646-653-7030
|
In
Australia:
Jane Lowe
IR
Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117
774
|
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Seven
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020, and for
AT/RT in June 2022.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
James Garner, Chief Executive
Officer, Managing Director.
View original
content:https://www.prnewswire.com/news-releases/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-esmo-301620371.html
SOURCE Kazia Therapeutics Limited